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Association between fasting 
glucose and all-cause mortality 
according to sex and age: a 
prospective cohort study
Sang-Wook Yi  1,2, Sangkyu Park3, Yong-ho Lee  4, Hyang-Jeong Park5, Beverley Balkau6 & 
Jee-Jeon Yi7
The association of fasting glucose with the risk of death according to sex and age remains unclear, 
and insufficient information is available on sex- and age-specific glucose concentrations within 
ethnic groups. This study analyzed a sample of 12,455,361 Korean adults who participated in health 
examinations during 2001–2004, and were followed up until 2013. Men had 3.0 mg/dL (0.167 mmol/L) 
higher mean glucose concentrations than women (94.7 vs. 91.7 mg/dL), although women over 73 years 
had higher levels. For glucose levels of 100–199 mg/dL, each 18 mg/dL (1 mmol/L) increase in fasting 
glucose increased mortality by 13% (HR = 1.13, [95% CI 1.12 to 1.13], p < 0.001). In individuals with 
fasting glucose levels of 100–125 mg/dL, each 18 mg/dL increase in fasting glucose was associated 
with a 30% increase in the risk for mortality (1.30, [1.18 to 1.43]) in those aged 18–34 years, a 32% 
increase (1.32, [1.26 to 1.39]) in those aged 35–44 years, and a 10% increase (1.10, [1.02 to 1.19]) in 
those aged 75–99 years. The fasting glucose levels associated with the lowest mortality were 80–94 mg/
dL regardless of sex and age. Prediabetes (100–125 mg/dL) was associated with higher mortality. The 
associations of hyperglycemia with mortality were stronger at younger ages.
Diabetes is a worldwide epidemic. Fasting glucose measurement remains the main test for the diagnosis of diabe-
tes and prediabetes, and it is a key indicator of future diabetes and cardiovascular disease1, 2. However, the current 
cut-points, for example, 100 or 110 mg/dL for prediabetes, are somewhat arbitrarily chosen due to inconsistent 
results in prior studies1–6. Identifying proper cut-points for fasting glucose and overall mortality would help 
inform public and clinical actions to prevent premature death from health issues related to hyperglycemia and 
hypoglycemia.
Although fasting glucose levels are generally known to increase with advancing age7–9 and may differ by sex8–10, 
the sex- and age-specific associations of fasting glucose with all-cause mortality have rarely been examined. It is 
unclear whether variation according to age and sex is present in the association between fasting glucose and the 
risk of death and/or the range of fasting glucose associated with a minimal risk of death7, 11, 12. Additionally, age- 
and sex-specific fasting glucose concentrations may differ across ethnic and regional groups8, 9, 13, meaning that 
the association of fasting glucose levels with diseases and mortality may also vary by ethnicity14. Furthermore, 
detailed sex- and age-specific fasting glucose concentrations in the Korean population have not been reported.
Through a large prospective cohort study that included 12.8 million participants, we set out to elucidate 
whether the association between fasting glucose levels and all-cause mortality varies by sex and age, and to 
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estimate sex- and age-specific levels of fasting glucose associated with minimal mortality. Precise estimates could 
help determine cut points for the management of hyperglycemia and hypoglycemia. Additionally, detailed esti-
mates of mean (and median) concentrations of fasting glucose according to sex and age could help in the manage-
ment of sex- and age- specific aspects of glucose metabolism and related metabolic disorders.
Methods
Study population and follow-up. The National Health Insurance Service (NHIS) provides compulsory 
health insurance that covers 97% of the Korean population. The Korean Metabolic Risk factor (KOMERIT) 
study was designed primarily to assess the risk of death associated with metabolic risk factors, and includes 
12,845,017 NHIS beneficiaries aged 18–99 years who participated in routine health examinations during 2001–
200415. Individuals with missing information on serum glucose, blood pressure, total cholesterol, and body-mass 
index (BMI) were excluded (n = 26,136), as were 3,665 persons with extremely low weight (<30 kg), high BMI 
(≥50 kg/m2), or short stature (<1.30 m in persons below 55 years, <1.10 m for those aged 55 years or older), and 
another 210 missing date of the health examination. Persons with self-reported diabetes (n = 369,645) were also 
excluded. The final study population included 12,455,361 participants, followed up until the 31st December 2013 
through the NHIS database of beneficiary status, with participants’ deaths being ascertained from the Resident 
Register of Korea15. All data are collected and maintained by the NHIS according to several Korean laws. For the 
research in accord with the conditions documented at Korean laws, health examination data can be provided to 
the researchers by the NHIS without specific informed consents from the participants. This study was approved 
by Institutional Review Board of Catholic Kwandong University, Republic of Korea. Anonymized data were pro-
vided to the authors by the NHIS, and they were only available through a specific computer within the NHIS 
headquarters.
Data collection. Fasting serum glucose and total cholesterol were assayed using enzymatic methods. Blood 
pressure was measured in a seated position using a standard mercury sphygmomanometer. Weight and height 
were measured to the nearest kg and cm, respectively15. BMI was calculated by weight in kilograms divided by the 
square of height in meters (kg/m2). Smoking history, alcohol use, and known diabetes status were self-reported 
via questionnaire. Health examination and data collection followed a standard protocol, the Health Examination 
Practice Guide, officially registered by the Ministry of Health and Welfare (Health Examination Practice Guide 
[Korean]. External quality assessment in clinical chemistry, such as fasting glucose measurement, for hospitals 
was supervised by the Korean Association of Quality Assurance for Clinical Laboratory, and assessments of the 
quality of assays were high16.
Data availability. The data that support the findings of this study are available from NHIS17, but restrictions 
apply to the availability of these data, which were used under license for the current study, and so are not publicly 
available.
Statistical analysis. For analysis, fasting serum glucose concentrations were mainly categorized into 
16 groups (<65, 65–69, 70–74, 75–79, 80–84, 85–89, 90–94 [Reference], 95–99, 100–104, 105–109, 110–117, 
118–125, 126–139, 140–169, 170–199, ≥200 mg/dL). Eight (or seven) groups (<70, 70–79, 80–94 [Reference], 
95–99, 100–109, 110–125, ≥126 [126–179, ≥180 mg/dL]), were used in additional analysis to show the differ-
ence in hazard ratios (HRs) for sex- and age-specific groups. The glucose category with the lowest mortality in 
sex and age-adjusted analysis was used as the referent. Fasting glucose level was also analyzed as a continuous 
variable and HRs per 18 mg/dL (1 mmol/L), rather than 10 mg/dL, increase in fasting glucose were calculated for 
between-study comparison3.
HRs for various fasting glucose categories with respect to the reference group were calculated using Cox 
proportional hazards models stratified by age (years) at baseline (18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 
75–84, 85–99) after adjustment for age at baseline (continuous variable; within each age group), sex (when appli-
cable), smoking status (current smoker, former smoker, never-smoker, and missing information [n = 627,788]), 
alcohol use (frequency; monthly or less, 2 days/month-2days/week, 3–7 days/week, and missing information 
[n = 487,379]), physical activity (at least once a weak; yes, and no), body-mass index (BMI; continuous variable), 
systolic blood pressure (continuous variable), serum total cholesterol (continuous variable). Age at baseline was 
stratified for analyses into six groups (18–35, 35–44, 45–54, 55–64, 65–74, 75–99 years). The HRs for a restricted 
cubic spline transformation of fasting glucose with 5 knots (70, 85, 100, 120, 140 mg/dL) with mortality in partic-
ipants having fasting glucose ≤300 mg/dL, were also plotted. Subgroup analyses with varying categories of fasting 
glucose served as sensitivity analyses.
Sex- and age-standardized death rates per 100,000 person-years (the simple mean of the applicable sex- and 
age-specific rates in 28 sex/age groups at ages 18–24 years, 25–29 years, and up to 85–99 years, increasing by 5 
year age groups, based on age attained during follow-up) was calculated for each fasting glucose group15. All 
p-values were two-sided. All analyses used SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
During 134.9 million person-years of follow-up of 12,455,361 people (43.1% women), 416,557 men and 215,832 
women died. At baseline the mean (standard deviation) age was 44.0(14.1) years and the mean fasting glucose 
level was 93.4(27.5) mg/dL (Table 1), 4.4% had fasting glucose levels 126 mg/dL or higher. Fasting glucose levels 
generally increased across six age groups (Tables S1–S3). Higher glucose levels were generally associated with 
higher BMI, systolic blood pressure, and total cholesterol values (Table S2).
Fasting glucose concentration according to sex and age. A unimodal distribution of fasting glucose 
was observed with a peak at 85–89 mg/dL (Figure S1). Men had 3.02 mg/dL (95% confidence interval [CI], 2.98 
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to 3.05) higher levels of fasting glucose than women. In men, the mean fasting glucose increased with age up 
until 62–63 years, while in women it did not substantially change up to 28–29 years and thereafter increased with 
age up to 86–99 years (Fig. 1, Table S3). Men and women had generally the same mean glucose levels at 18–23 
Characteristics Classification Total Men Women
Age, years Mean (±SD) 44.0 ± 14.1 42.9 ± 13.2 45.5 ± 15.1
Fasting serum 
glucose, mg/dL Mean (±SD) 93.4 ± 27.5 94.7 ± 28.8 91.7 ± 25.6
BMI, kg/m2 Mean (±SD) 23.5 ± 3.2 23.8 ± 3.0 23.0 ± 3.3
Systolic blood 
pressure, mmHg Mean (±SD) 123.9 ± 17.2 126.1 ± 16.1 121.0 ± 18.1
Total cholesterol, 
mg/dL Mean (±SD) 194.0 ± 48.7 194.0 ± 47.1 193.9 ± 50.8
Sex
Men 7,090,089(56.9) 7,090,089(100.0) 0(0.0)
Women 5,365,272(43.1) 0(0.0) 5,365,272(100.0)
Fasting serum 
glucose, mg/dL
<70 285,924(2.3) 157,981(2.2) 127,943(2.4)
70–79 2,381,520(19.1) 1,299,853(18.3) 1,081,667(20.2)
80–89 3,576,623(28.7) 1,910,731(26.9) 1,665,892(31.0)
90–99 3,159,827(25.4) 1,787,246(25.2) 1,372,581(25.6)
100–125 2,505,235(20.1) 1,567,046(22.1) 938,189(17.5)
126–169 373,640(3.0) 248,713(3.5) 124,927(2.3)
≥170 172,592(1.4) 118,519(1.7) 54,073(1.0)
Smoking status
Current smoker 3,565,515(28.6) 3,397,467(47.9) 168,048(3.1)
Never smoker 7,200,954(57.8) 2,438,776(34.4) 4,762,178(88.8)
Former smoker 1,061,104(8.5) 979,690(13.8) 81,414(1.5)
Missing 627,788(5.0) 274,156(3.9) 353,632(6.6)
Alcohol use
Monthly or less 5,886,404(47.3) 2,110,523(29.8) 3,775,881(70.4)
2/week–2/month 4,883,807(39.2) 3,627,965(51.2) 1,255,842(23.4)
3–7 days/week 1,197,771(9.6) 1,096,946(15.5) 100,825(1.9)
Missing 487,379(3.9) 254,655(3.6) 232,724(4.3)
Physical activity at 
least once a week
No 7,466,247(59.9) 3,694,570(52.1) 3,771,677(70.3)
Yes 4,989,114(40.1) 3,395,519(47.9) 1,593,595(29.7)
Age, years
18–34 3,711,950(29.8) 2,279,667(32.2) 1,432,283(26.7)
35–44 3,214,771(25.8) 2,017,090(28.4) 1,197,681(22.3)
45–54 2,633,280(21.1) 1,388,966(19.6) 1,244,314(23.2)
55–64 1,745,729(14.0) 876,433(12.4) 869,296(16.2)
65–74 913,306(7.3) 424,218(6.0) 489,088(9.1)
75–99 236,325(1.9) 103,715(1.5) 132,610(2.5)
Table 1. Characteristics of participants (n = 12,455,361). Abbreviation: BMI, body-mass index; SD, standard 
deviation. The difference for each characteristic was tested using ANOVA and the chi-square test, and the 
p-value for each variable, including total cholesterol, was <0.0001. To convert glucose from mg/dL to mmol/L, 
multiply by 0.0555. To convert cholesterol from mg/dL to mmol/L, multiply by 0.0259.
Figure 1. Mean and median concentration of fasting glucose. To convert glucose from mg/dL to mmol/L, 
multiply by 0.0555.
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years; thereafter, men had higher glucose levels up to around 72–73 years and women over 73 years had higher 
levels than men. The difference in glucose levels between sexes peaked at 48–51 years, when men had a 6.1 mg/dL 
higher mean glucose level compared with women.
Associations between fasting glucose and mortality. J-curve-like associations between fasting 
glucose levels and mortality, with a nadir at around 80–94 mg/dL in both men and women (Fig. 2, Figure S5, 
Table S4) and in each sex/age group (Fig. 3. Table S5), were observed. HRs generally began to rise at fasting 
glucose levels around 95–100 mg/dL in each sex/age group, and began to rise from around 80 mg/dL and lower.
For glucose levels of 100–199 mg/dL assuming a log-linear relationship, the HRs per 18 mg/dL (1 mmol/L) 
increase in fasting glucose were 1.13 (95% CI, 1.12 to 1.13) in men and 1.12 (1.11 to 1.13) in women (Table 2). 
The associations were similar between sexes in all ages combined (Pinteraction = 0.190), while women had stronger 
association than men in the age group of 65–74 years (HR per each 18 mg/dL increase = 1.13 in women vs. 1.11 in 
men, Pinteraction = 0.012) in the sex- and age-specific analysis. For glucose levels below 100 mg/dL, the inverse asso-
ciations between fasting glucose and mortality were stronger in men than in women (Pinteraction = 0.014), especially 
in the age groups of 55–64 and 75–99 years.
In the age-specific analysis for glucose levels of 100–199 mg/dL, the HRs per 18 mg/dL (1 mmol/L) increase in 
fasting glucose were 1.17 (95% CI, 1.16 to 1.19) in the age group of 35–44 years and 1.09 (95% CI, 1.08 to 1.09) in 
the age group of 75–99 years (Fig. 4). When the analysis was restricted to subjects whose levels were 100–125 mg/
dL, the HRs per 18 mg/dL higher fasting glucose were 1.30 in those aged 18–34 years, 1.32 in those aged 35–44 
years, and 1.12 in those aged 75–99 years. The HRs per 18 mg/dL higher fasting glucose were generally highest in 
the age group of 35–44 years and thereafter gradually decreased with age (Pinteraction between age groups < 0.001 
in both the 100–125 and 100–199 mg/dL ranges). The inverse associations in the range below 100 mg/dL were 
similar across age groups (Pinteraction = 0.198).
Discussion
Fasting glucose levels 80–94 mg/dL were associated with the lowest mortality regardless of sex and age, whereas 
glucose levels 100 mg/dL and above were clearly associated with higher mortality. Therefore, if the term ‘normo-
glycemia’ were to be used for glucose levels associated with the lowest mortality risk2, 100 mg/dL18 rather than 
110 mg/dL2 might be a more appropriate upper limit of normoglycemia. Our age-stratified analysis showed that 
prediabetes ranges were relatively strongly associated with increased mortality, especially at younger ages (e.g., in 
men at 35–44 years, HR = 1.45, 95% CI, 1.37 to 1.54 in men with glucose levels 118–125 mg/dL compared to men 
with 90–94 mg/dL; Table S5). Overall, in the range of 100 mg/dL or above, HRs per increasing fasting glucose lev-
els were generally stronger in younger adults than in older adults. In the lower glucose range, there was evidence 
that the risk of mortality starts increasing from around 80 mg/dL in line with previous research in Koreans4, but 
this may be discordant with a collaborative study in which levels of 70–100 mg/dL were not associated with higher 
risk3, however the population studied was much smaller than our population.
Fasting glucose levels generally increased with age and were higher in men compared with women, consistent 
with previous research8, 9. Our analysis further showed that glucose levels are similar between sexes at 18–21 
years and begin to rise in men around the early 20s compared to the late 20s in women. Men had higher mean 
glucose levels than women from the early 20s to the early 70s; thereafter, women had higher levels than men. The 
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Figure 2. Hazard ratios* associated with 16 categories of baseline fasting serum glucose (FSG) for mortality, 
according to sex. FSG categories (mg/dL: <65, 65–69, 70–74, 75–79, 80–84, 85–90, 90–94 [Reference], 
95–99, 100–104, 105–109, 110–117, 118–125, 125–139, 140–169, 170–199, ≥200). The midpoint was used as 
a representative value for each FSG category, except for both ends (61 and 248), for which the median of all 
participants was used. *Hazard ratios and 95% confidence intervals were calculated using Cox proportional 
hazard models stratified by baseline age (years: 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, 85–99), after 
adjustment for age at baseline (continuous variable), sex (if applicable), smoking status, alcohol use, physical 
activity, body-mass index, systolic blood pressure, and total cholesterol levels. To convert glucose from mg/dL to 
mmol/L, multiply by 0.0555.
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difference in glucose levels between sexes peaked at 48–51 years. A number of factors including sex hormones, 
visceral adiposity, and muscle mass have been reported to regulate glucose metabolism19–22. Sex- and age-specific 
changes in sex hormones23, muscle mass24, and body adiposity25 generally concur with the observed sex- and 
age-specific changes in fasting glucose in our study. For example, small difference in mean BMI in women 18–29 
years (21.1 kg/m2 at 18–19 years and 20.9 kg/m2 at 28–29 years) is concordant with no increase in mean fasting 
glucose. Furthermore, a well-known sharp decline in estrogen around the time of menopause corresponds with a 
sharp increase in fasting glucose in women around 50 years in the present study.
A recent systematic review showed that impaired fasting glucose as defined by the American Diabetes 
Association (IFG-ADA, fasting glucose of 100–125 mg/dL) was associated with higher mortality by 13% (relative 
risk [RR] = 1.13, 95% CI, 1.02 to 1.25) in all eligible studies, and by 9% (1.09, 0.97 to 1.22) in smoking-adjusted 
studies26. In this systematic review, IFG-ADA was associated with higher mortality in younger persons with an 
average age <55 years (RR = 1.28, 95% CI = 1.13 to 1.46), and in studies in which individuals with baseline car-
diovascular disease were not excluded (1.19, 1.03 to 1.38), whereas such an association was not found in older 
persons (age ≥55 years) (1.04, 0.96 to 1.13) or in studies that excluded individuals with baseline cardiovascular 
disease (1.02, 0.86 to 1.19). In our study, the multivariate, smoking status-adjusted HRs associated with IFG-ADA 
were 1.12 (1.11 to 1.13) compared to normoglycemia (70–99 mg/dL) (Table S6). Although the associations of 
  a 18-34 years old   b 35-44 years old 
  c 45-54 years old   d 55-64 years old 
  e 65-74 years old   f 75-99 years old 
Men  
Women 
Figure 3. Hazard ratios* for mortality according to age by restricted cubic splines of fasting serum glucose 
with five knots (70, 85, 100, 120, and 140 mg/dL) and 90 mg/dL as a reference in men (n = 7,043,405) and 
women (n = 5,356,918) having fasting glucose ≤300 mg/dL. *Hazard ratios and 95% confidence intervals were 
calculated using the same method as in Fig. 2. To convert glucose from mg/dL to mmol/L, multiply by 0.0555.
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IFG-ADA were generally greater at younger ages (e.g., HR at 35–44 years = 1.17; 95% CI, 1.14 to 1.20), the oldest 
persons, aged 75–99 years at baseline, also had a higher mortality associated with IFG-ADA (1.08, 1.07 to 1.10) 
in the current study. Additionally, excluding persons with comorbid heart diseases or stroke (n = 137,708) only 
changed the association of IFG-ADA with mortality very slightly (1.12, 1.11 to 1.13; identical to 3 decimal places 
between with vs. without exclusion), with similar findings also observed for other glucose categories. Overall, our 
study provided a much more precise estimation of relative risk associated with IFG than the previous systematic 
review.
Considering the fairly strong relative risk associated with prediabetes (100–125 mg/dL), younger individuals 
with prediabetic glucose levels (particularly 110–125 mg/dL), should be carefully managed to prevent premature 
death. Individuals whose glucose is below 80 mg/dL (especially below 70 mg/dL) should be followed clinically.
Three large clinical trials in diabetic populations, failed to show a beneficial effect of intensive glycemic control 
on overall mortality and major vascular complications27–30, whereas the Diabetes Control and Complications 
Trial (DCCT)/the Epidemiology of Diabetes Interventions and Complications (EDIC) study, and the follow-up 
study in the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that better glycemic control 
reduced vascular complications and all-cause mortality31, 32. The participants in the DCCT/EDIC and UKPDS 
were younger and had less pre-existing cardiovascular complications than trials that showed no beneficial effect 
of intensive glycemic control on mortality. Our analysis showed that the estimated relative risk associated with 
increasing fasting glucose levels generally weakened with advancing age. These results suggest that glucose lower-
ing interventions may be more beneficial for younger persons with fewer vascular complications33. In this regard, 
glycemic management in younger adults with prediabetic hyperglycemia (as well as those with diabetes) may be 
beneficial for preventing premature death.
The very large number of people and the complete follow-up for death are clear strengths of the study; how-
ever, its limitations are to be considered. Causal inference may be limited because of the observational nature 
of the study. Information on cause-specific mortality was not available due to privacy issues. Other measures 
of glucose tolerance such as postprandial glucose and HbA1c were also unavailable. Some potential confound-
ers including socioeconomic status and dietary factors were not adjusted for in the main analysis. Including a 
socioeconomic status variable (decile of National Health Insurance premium that is determined by income and 
assets34; <4th decile, 4th-7th decile, ≥8th decile) in the subpopulation analysis, however, showed no change in the 
findings. Nevertheless, unadjusted and residual confounding might affect the study results. Information on fast-
ing glucose and other variables might vary in quality depending on the time and the hospitals. However, since 
the potential variability in data quality by hospitals would most likely be non-differential according to mortality, 
it would be unlikely to overestimate the associations. Nonetheless, this is a limitation of the study. Relative risk 
FSG 
range
Age 
group Men Women p value for interaction 
between 
sexesmg/dL years
No. of 
death p-value HR (95% CI)
No. of 
death p-value HR (95% CI)
100–199
All ages 149,904 <0.001 1.13 (1.12–1.13) 74,105 <0.001 1.12 (1.11–1.13) 0.190
18–34 3,235 <0.001 1.15 (1.10–1.19) 491 0.060 1.12 (1.00–1.27) 0.737
35–44 11,251 <0.001 1.17 (1.15–1.19) 2,031 <0.001 1.17 (1.12–1.23) 0.953
45–54 22,746 <0.001 1.15 (1.14–1.17) 5,250 <0.001 1.13 (1.10–1.16) 0.255
55–64 39,240 <0.001 1.14 (1.13–1.15) 13,030 <0.001 1.14 (1.13–1.16) 0.914
65–74 48,086 <0.001 1.11 (1.10–1.12) 28,143 <0.001 1.13 (1.12–1.14) 0.012
75–99 25,346 <0.001 1.08 (1.07–1.10) 25,160 <0.001 1.10 (1.08–1.11) 0.146
100–125
All ages 112,683 <0.001 1.20 (1.18–1.22) 56,842 <0.001 1.19 (1.16–1.22) 0.537
18–34 2,823 <0.001 1.30(1.17–1.44) 454 0.118 1.25 (0.95–1.64) 0.769
35–44 8,965 <0.001 1.31 (1.24–1.39) 1,770 <0.001 1.36 (1.20–1.56) 0.576
45–54 17,138 <0.001 1.24 (1.20–1.29) 4,414 <0.001 1.32 (1.22–1.43) 0.195
55–64 28,822 <0.001 1.21 (1.18–1.25) 10,248 <0.001 1.20 (1.14–1.26) 0.642
65–74 35,940 <0.001 1.17 (1.14–1.20) 21,321 <0.001 1.19 (1.15–1.23) 0.369
75–99 18,995 <0.001 1.12 (1.08–1.16) 18,635 <0.001 1.13 (1.09–1.18) 0.566
<100
All ages 254,446 <0.001 0.95 (0.94–0.96) 136,371 <0.001 0.96 (0.95–0.98) 0.014
18–34 12,584 0.917 1.00 (0.96–1.03) 4,051 0.150 0.95 (0.89–1.02) 0.227
35–44 23,904 <0.001 0.95 (0.92–0.97) 8,167 0.482 0.98 (0.94–1.03) 0.197
45–54 37,576 0.001 0.97 (0.95–0.99) 14,725 0.004 0.95 (0.92–0.98) 0.451
55–64 61,212 <0.001 0.93 (0.92–0.95) 26,023 0.080 0.98 (0.95–1.00) 0.004
65–74 78,387 <0.001 0.95 (0.93–0.96) 46,632 <0.001 0.95 (0.94–0.97) 0.592
75–99 40,783 <0.001 0.95 (0.93–0.96) 36,773 0.038 0.98 (0.96–1.00) 0.019
Table 2. HRsa per 18 mg/dL (1 mmol/L) FSG increase according to sex, age, and FSG range. CI, confidence 
interval; FSG, fasting serum glucose; HR, hazard ratio. aHRs were calculated by Cox models stratified by age 
(baseline age, years: 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, 85–99), after adjustement for age at 
baseline, sex (if applicable), smoking status, alcohol use, physical activity, body mass index, systolic blood 
pressure, and total cholesterol. To convert glucose from mg/dL to mmol/L, multiply by 0.0555.
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based on a single measurement of fasting glucose may underestimate the true association, due to a regression 
dilution effect35.
The fasting glucose range associated with the lowest mortality may be able to be generalized to other ethnic 
populations, since the range was generally the same across various sex and age groups that had varying car-
diometabolic risk profiles. However, our study populations were generally leaner than other, more specifically 
European-origin, populations and had only a few smokers in women15. Further, accessibility to healthcare 
also affects the risk of complications, and deaths related to dysglycemia including diabetes36. Therefore, some 
results, such as the magnitude of relative risk associated with fasting glucose for all-cause mortality, may need 
to be assessed in other populations with varying distributions of risk factors, and varying access to healthcare 
utilization.
In conclusion, this large prospective cohort study showed a J-curve association, in which low and high fast-
ing glucose concentrations were associated with higher mortality in the general population. The optimal fasting 
glucose levels for mortality (80–94 mg/dL) were generally the same regardless of sex and age, while the relative 
risk associated with increasing fasting glucose above those levels was greater at younger ages than at older ages. 
Prediabetic hyperglycemia was associated with excess mortality, especially in the range of 110–125 mg/dL.
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